HealthTech Investor Marketing: Building Credibility Before You Pitch

HealthTech investor marketing is what an investor finds when she looks. Before a deck is read, she has opened the website, searched the founder’s name, read whatever customers have said in public, and asked a colleague who has seen the space. The pitch either confirms what she found or contradicts it, and a pitch that contradicts a thin website loses to the company whose website did the pitching in advance. This is marketing work, and it is done months before the raise.

The market is crowded and well read. Rock Health recorded $6.4 billion of US digital health funding across 245 deals in the first half of 2025, at an average of $26.1 million per deal. An investor active in the sector compares each new company with the two hundred she saw last quarter, and HealthTech investor marketing decides what she finds when the comparison starts on the website. Gartner reports 75% of B2B buyers prefer a rep-free experience; investors research the same way, without asking.

This guide sets out four HealthTech investor marketing moves for the founder or head of marketing at a HealthTech company six to twelve months from a raise. None of them is advice on valuation, terms or which investors to approach; all of them are about the evidence and the presence an investor sees before she agrees to a meeting. Our pillar on HealthTech go-to-market strategy covers the commercial engine the investor is evaluating, and our guide to HealthTech revenue marketing covers the numbers she asks about first.

1. Make the commercial evidence public

The first move is to put the evidence an investor will ask for where she can find it before she asks. Case studies with outcomes and baselines from named organisation types. The regulatory status and certifications. The integration listings on the record system vendors’ marketplaces. A pricing model page. HealthTech investor marketing treats the public evidence as the first page of the data room, because an investor who has read it arrives at the meeting asking second-order questions.

The evidence an investor checks first

Whether real organisations use the product and what changed for them. Then whether the claims survive a regulator’s reading. And whether the security posture would pass a hospital’s review, and whether the pricing model suggests a business that scales. Each is a page, and each is HealthTech investor marketing. TrustRadius found 78% of B2B buyers already knew the products they bought before the purchase began. An investor who has seen two hundred decks knows which companies’ evidence she could find and which she could not.

Inside the rules

Every outcome on the public pages sits inside what the regulatory status permits. In the US the FTC’s Health Products Compliance Guidance requires “competent and reliable scientific evidence” for health claims, and an investor’s diligence will read the site against it. A claim the company cannot support is a diligence finding before it is a HealthTech investor marketing problem. Our guide to healthcare case study pages covers writing outcomes the legal team signs off.

2. Build the founder’s voice where investors read

The second move is the founder’s public presence. An investor searches the founder’s name before the meeting and reads what comes back: the profile, the posts, the interviews, the data the founder has published. A founder who has written nothing is a founder the investor has to meet to assess. HealthTech investor marketing builds the voice in advance: a clear view of the problem, published consistently, with original data where the company has it, in the places the sector’s investors read.

What the voice says

The problem in the buyer’s setting, seen from inside it. The contrarian view the company’s position depends on. What the company has learned from its customers, with the numbers it can share. Never the product’s feature list, and never a post that could have been written by any founder in the category, because HealthTech investor marketing is the founder being told apart. Google’s guidance on helpful content weights experience and expertise more heavily on health topics, and the founder’s byline on the evidence page is where both are shown.

Original data as the founder’s asset

A benchmark built from a survey of the company’s own buyer type, published under the founder’s name, is the single HealthTech investor marketing asset that reaches investors, journalists and buyers at once. Ten findings, the method stated, one surprise. At Healthora, we have seen that a founder with one published piece of original data tends to be introduced to investors by people who cited it, rather than having to ask for the introduction.

3. Make the site read like a fundable company

The third move is the website, which an investor reads as a proxy for the company’s commercial competence. A homepage that cannot say who the product is for, an about page with first names and a mission, and a pricing page that says “contact us” all say the same thing. The company has not yet learned to sell. HealthTech investor marketing makes the site read like a company that already knows its buyer. A first screen with one job, named people with credentials, a fit statement, a pricing model, and a demo path that works.

The three pages the investor opens

The homepage, to see whether the company can state its buyer and its outcome in a sentence. Then the about page, to see who the people are and whether any of them have worked in a clinic or run a hospital’s information governance. The pricing page, to see whether the model suggests a business that scales. In HealthTech investor marketing the second is the one that matters most, and our guide to HealthTech about page copy covers it, which is the page investors read most and companies write least.

The numbers the site can show

Customers by setting and scale, live since when, certifications held, funding to date in plain words. Never pipeline, never revenue, never the metrics that belong in the data room. HealthTech investor marketing shows the shape of the business on the site; the meeting shows the numbers. A site that shows nothing suggests there is nothing, and a site that shows too much suggests nobody decided what was confidential.

4. Run the investor list like an account campaign

The fourth move borrows from account-based marketing. A named list of the twenty to forty investors who have backed companies like this one, in this sector, at this stage. For each, the partner who leads health, what she has written, and who could introduce the founder. Then a quarterly update, sent to the list before the raise, with three numbers and one lesson, so that when the deck arrives the reader has been following the company for a year. HealthTech investor marketing is a relationship built before it is needed.

The quarterly update

One page. What changed in the quarter, three numbers the company is willing to share, one thing learned from customers, one ask. Sent to the list and to advisers, four times a year, whether or not a raise is planned, the update is HealthTech investor marketing at its cheapest. An investor who has read four updates opens the deck already knowing the trajectory, and the meeting is about the next chapter rather than the first.

The metrics page behind the update

A private page, shared by link with investors who ask, carrying the numbers the company tracks: qualified pipeline by source, the sales cycle, the pilot conversion rate, the renewal rate. Kept current monthly as part of HealthTech investor marketing, so the answer to “can you send the latest numbers” is a link. At Healthora, we have seen that companies which run the investor list this way tend to find that the first meeting of the raise is with someone who asked for it. That changes the conversation entirely. HBR’s research on growth stalls found most stalls have controllable causes, and a raise that starts cold, with a list built the month before, is one of them.

HealthTech investor marketing in practice: the six months before

HealthTech investor marketing runs for six months before the deck. Month one runs the investor’s ten-minute read and builds the named list. Then months two and three publish the evidence: the case studies with outcomes, the regulatory and security pages, the pricing model, the about page with people who can be checked. Month four fields the founder’s benchmark survey and starts the founder’s voice in the two publications the list reads. Months five and six send the first two quarterly updates, publish the benchmark, and set up the private metrics page.

The HealthTech investor marketing change shows first in how the meetings start. The investor has read the evidence, seen the benchmark cited, and followed two updates, and the first question is about the next chapter. Then the introductions start arriving from people who cited the data. A raise that opens with a warm list and a site that already pitched is a different raise from one that opens cold. The same six months of work also built the pipeline the investor asks about first.

The recap below lists the four moves in the order to make them.

The four HealthTech investor marketing moves can be made by the founding team, by a specialist agency, or by the two together. Our services and case studies show what the evidence and positioning work looks like in engagements we have run, and our guide to why HealthTech startups stall after early traction covers the pattern investors are most alert to.

A specialist in health understands that an investor reads the company as a hospital buyer does. The evidence both of them check is the same, and a founder’s published data reaches both at once. Publish the evidence, build the voice, fix the site, and run the list. Then the pitch confirms what the investor already found.

Frequently asked questions

Keep reading

More on the commercial engine an investor is evaluating: